Related Experiment Video
Updated: May 29, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Pneumocystis jirovecii pneumonia in developing countries
Y de Armas Rodríguez1, G Wissmann, A L Müller
1Pathology Department, Institute of Tropical Medicine "Pedro Kourí", Ciudad de la Habana, Cuba.
Pneumocystis pneumonia (PcP) is a significant fungal infection in immunocompromised individuals. This review highlights its increasing prevalence in developing nations, particularly among AIDS patients, between 2002 and 2010.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Epidemiology
Background:
- Pneumocystis pneumonia (PcP) is a severe opportunistic infection primarily affecting immunocompromised patients.
- The epidemiology and clinical presentation of PcP are well-established in developed countries.
- Limited data exists regarding the prevalence and characteristics of PcP in developing countries.
Purpose of the Study:
- To review and synthesize existing literature on Pneumocystis pneumonia in developing countries.
- To assess the prevalence and trends of PcP in various geographic regions.
- To understand the clinical spectrum of PcP in the context of global health.
Main Methods:
- A systematic review of published articles was conducted.
- Studies focusing on African, Asian, and American countries were included.
- Data on PcP prevalence and patient demographics were extracted and analyzed.
Main Results:
- Pneumocystis pneumonia was confirmed as a frequent opportunistic infection in Human Immunodeficiency Virus (HIV)-positive patients across different regions.
- A discernible increasing trend in PcP incidence was observed in developing countries from 2002 to 2010.
- The study identified PcP as a significant health concern in resource-limited settings.
Conclusions:
- Pneumocystis pneumonia remains a critical threat to immunocompromised populations globally.
- There is an urgent need for increased awareness and improved diagnostics for PcP in developing nations.
- Continued surveillance is essential to monitor trends and inform public health strategies for PcP management.
Related Concept Videos
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

